Okay, let's tackle this question. The user is asking about the most common genetic mutation in a 50-year-old obese, postmenopausal woman with endometrial cancer. First, I need to recall the common genetic mutations associated with endometrial cancer. Endometrial cancer has two main types: Type I and Type II. Type I is more common and is associated with estrogen excess, often seen in obese women, and is linked to mutations in PTEN. Type II is less common, more aggressive, and associated with mutations like TP53.

The patient is postmenopausal and obese, which are risk factors for Type I endometrial cancer. So the most likely mutation here would be PTEN. PTEN is a tumor suppressor gene, and its loss leads to activation of the PI3K/AKT/mTOR pathway, promoting cell proliferation.

Now, looking at the options (even though they aren't listed), the correct answer is PTEN. The other options might include things like KRAS, which is found in some cancers but not the most common here. TP53 is more for Type II. BRAF is another possibility in some cancers, but again, less common in Type I endometrial cancer.

Wait, I should double-check. Some sources mention that about 60% of Type I endometrial cancers have PTEN mutations. Also, there's Lynch syndrome (HNPCC) which is a hereditary form, but that's more about microsatellite instability and mutations in MLH1, MSH2, etc., but the question is about the commonest mutation in sporadic cases. So PTEN is the key here.

So the clinical pearl would be that PTEN mutations are most common in Type I endometrial cancer, which is estrogen-driven and associated with obesity and postmenopause. The other options like TP53 are for Type II. Also, remembering that PTEN is a tumor suppressor gene and its mutation leads to activation of a specific pathway is important for exams.

**Core Concept**
Endometrial cancer is classified into estrogen-dependent (Type I) and non-estrogen-dependent (Type II) subtypes. Type I, common in obese postmenopausal women, is strongly associated with *PTEN* gene mutations, which disrupt the PI3K/AKT/mTOR signaling pathway, promoting uncontrolled cell growth.

**Why the Correct Answer is Right**
*PTEN* (phosphatase and tensin homolog) is the most frequently mutated tumor suppressor gene in Type I endometrial cancer, occurring in ~40-60% of cases. Loss of *PTEN* function activates the PI3K/AKT/mTOR pathway, driving endometrial hyperplasia and malignancy. Obesity-related insulin resistance and hyperinsulinemia further exacerbate this pathway, linking metabolic syndrome to endometrial carcinogenesis.

**Why Each Wrong Option is Incorrect**
**Option A:** *KRAS* mutations are rare in endometrial cancer and more commonly found in colorectal or lung cancers.
**Option B:** *TP53* mutations are hallmark of Type II endometrial cancer, which is aggressive, hormone-unrelated, and less common.
**Option C:** *BRAF* mutations are uncommon in endometrial cancer; they are more relevant in papillary thyroid or melanoma

✓ Correct Answer: B. PTEN